id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-300320-07tdrd4w	Siordia, Juan A.	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials	2020-07-15		.txt	text/plain	4829	372	44	Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Medical therapies investigated included lopinavir/ritonavir, arbidol, hydroxychloroquine, remdesivir, favipiravir, heparin, glucocorticoids, interferon, ivermectin, and convalescent plasma. Key words included COVID-19, SARS-CoV2, randomized, This article is part of the Topical Collection on Covid-19 controlled, human, retrospective, prospective, trial, chloroquine, hydroxychloroquine, lopinavir, ritonavir, arbidol, umifenovir, tocilizumab, favipiravir, steroids, dexamethasone, glucocorticoids, interferon, ivermectin, remdesivir, azithromycin, heparin, and low-molecular weight heparin. Lopinavir/ritonavir, arbidol, hydroxychloroquine, favipiravir, remdesivir, and heparin are medications that have been tested in human controlled trials for COVID-19 treatment. In human trials, arbidol shows no significant positive-negative conversion rate or recovery time compared to standard therapy or lopinavir/ritonavir [4, 9] . Combining T, treatment group (remdesivir); C, control group all the hydroxychloroquine human trials showed no benefit with reducing COVID-19 viral shedding time.	./cache/cord-300320-07tdrd4w.txt	./txt/cord-300320-07tdrd4w.txt